BTIG Reiterates Buy on ImmunityBio, Maintains $12 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 86.7%

Neg 0% Neu 86.7% Pos 0%

BTIG analyst Jeet Mukherjee reiterates ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $12 price target.

Comments

No comments yet. Be the first!